UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy, Tolerability, and Safety of DFN‐15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study

Headache, 2020-01, Vol.60 (1), p.58-70

2020

Volltextzugriff (PDF)

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

Clinical therapeutics, 2010-07, Vol.32 (7), p.1234-1251

2010

Volltextzugriff (PDF)

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

BMC neurology, 2011-05, Vol.11 (1), p.57-57, Article 57

2011

Volltextzugriff (PDF)

DFN‐02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double‐Blind, Placebo‐Controlled Study

Headache, 2018-05, Vol.58 (5), p.676-687

2018

Volltextzugriff (PDF)

Connexin43, the major gap junction protein of astrocytes, is down-regulated in inflamed white matter in an animal model of multiple sclerosis

Journal of neuroscience research, 2005-06, Vol.80 (6), p.798-808

2005

Volltextzugriff (PDF)

A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults

Headache, 2016-10, Vol.56 (9), p.1455-1465

2016

Volltextzugriff (PDF)

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study

Journal of headache and pain, 2018-08, Vol.19 (1), p.69-9, Article 69

2018

Volltextzugriff (PDF)

AMPA/kainate receptors in mouse spinal cord cell-specific display of receptor subunits by oligodendrocytes and astrocytes and at the nodes of Ranvier

Glia, 2003-04, Vol.42 (1), p.12-24

2003

Volltextzugriff (PDF)

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study

Journal of headache and pain, 2018-08, Vol.19 (1), p.70-8, Article 70

2018

Volltextzugriff (PDF)

Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs

Patient preference and adherence, 2017-01, Vol.11, p.121-129

2017

Volltextzugriff (PDF)

Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors

The Journal of pharmacology and experimental therapeutics, 1998-03, Vol.284 (3), p.966

1998

Volltextzugriff (PDF)

A Randomized, Double-Blind, Placebo-Controlled, Study Evaluating the Efficacy of DFN-02 (Nasal Spray of Sumatriptan 10 mg + Permeation Enhancer) in Migraine With or Without Aura (P4.149)

Neurology, 2018, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Select ionotropic glutamate AMPA/kainate receptors are expressed at the astrocyte–vessel interface

Brain research, 2004-05, Vol.1007 (1), p.178-182

2004

Volltextzugriff (PDF)

Subjects with Episodic Migraine Treated with DFN-02 (Sumatriptan 10 mg + the permeation enhancer DDM) Report Higher Treatment Satisfaction and Reduced Functional Disability Compared with Placebo (P4.124)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Safety and Tolerability of Ubrogepant for the Acute Treatment of Migraine in Participants Taking Atogepant for the Preventive Treatment of Episodic Migraine: Results from the TANDEM Trial (S22.005)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Efficacy of Ubrogepant for the Treatment of Migraine Symptoms During the Prodrome (Premonitory Phase): Results From the PRODROME Trial (S47.002)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Efficacy of ubrogepant for the treatment of migraine symptoms during the prodrome (premonitory phase): Results from the prodrome trial

Journal of the neurological sciences, 2023-12, Vol.455, p.121630, Article 121630

2023

Volltextzugriff (PDF)

Randomized, Double-Blind, Pilot Study Comparing 3 Mg Subcutaneous Sumatriptan With 6 Mg Subcutaneous Sumatriptan Using DFN-11 Autoinjector for the Acute Treatment Of Rapidly-Escalating Migraine Attacks (P1.10-007)

Neurology, 2019-04, Vol.92 (15_supplement)

2019

Volltextzugriff (PDF)

Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis

Experimental neurology, 2004-09, Vol.189 (1), p.5-9

2004

Volltextzugriff (PDF)

DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment

CNS drugs, 2019-04, Vol.33 (4), p.375-382

2019

Volltextzugriff (PDF)

Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine

Journal of headache and pain, 2017-12, Vol.18 (1), p.17-8, Article 17

2017

Volltextzugriff (PDF)

A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine

Journal of headache and pain, 2017-12, Vol.18 (1), p.31-8, Article 31

2017

Volltextzugriff (PDF)

Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients

Medical devices (Auckland, N.Z.), 2016-01, Vol.9 (Issue 1), p.131-137

2016

Volltextzugriff (PDF)

(±)-α-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid and kainate receptor subunit expression in mouse versus rat spinal cord white matter: similarities in astrocytes but differences in oligodendrocytes

Neuroscience letters, 2003-07, Vol.345 (2), p.126-130

2003

Volltextzugriff (PDF)

Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans

Drug design, development and therapy, 2015-01, Vol.9, p.3293-3300

2015

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(20)

Publikationsform

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Headache And Pain
(4)
Neurology
(4)
Headache
(3)
The journal Of Headache And Pain
(3)
Bmc Neurology
(1)
Brain Research
(1)
Clinical Therapeutics
(1)
Cns Drugs
(1)
Drug Design, Development And Therapy
(1)
Experimental Neurology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy, Tolerability, and Safety of DFN‐15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

DFN‐02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double‐Blind, Placebo‐Controlled Study

Connexin43, the major gap junction protein of astrocytes, is down-regulated in inflamed white matter in an animal model of multiple sclerosis

A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study

AMPA/kainate receptors in mouse spinal cord cell-specific display of receptor subunits by oligodendrocytes and astrocytes and at the nodes of Ranvier

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study

Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs

Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors

A Randomized, Double-Blind, Placebo-Controlled, Study Evaluating the Efficacy of DFN-02 (Nasal Spray of Sumatriptan 10 mg + Permeation Enhancer) in Migraine With or Without Aura (P4.149)

Select ionotropic glutamate AMPA/kainate receptors are expressed at the astrocyte–vessel interface

Subjects with Episodic Migraine Treated with DFN-02 (Sumatriptan 10 mg + the permeation enhancer DDM) Report Higher Treatment Satisfaction and Reduced Functional Disability Compared with Placebo (P4.124)

Safety and Tolerability of Ubrogepant for the Acute Treatment of Migraine in Participants Taking Atogepant for the Preventive Treatment of Episodic Migraine: Results from the TANDEM Trial (S22.005)

Efficacy of Ubrogepant for the Treatment of Migraine Symptoms During the Prodrome (Premonitory Phase): Results From the PRODROME Trial (S47.002)

Efficacy of ubrogepant for the treatment of migraine symptoms during the prodrome (premonitory phase): Results from the prodrome trial

Randomized, Double-Blind, Pilot Study Comparing 3 Mg Subcutaneous Sumatriptan With 6 Mg Subcutaneous Sumatriptan Using DFN-11 Autoinjector for the Acute Treatment Of Rapidly-Escalating Migraine Attacks (P1.10-007)

Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis

DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment

Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine

A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine

Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients

(±)-α-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid and kainate receptor subunit expression in mouse versus rat spinal cord white matter: similarities in astrocytes but differences in oligodendrocytes

Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans

Suchergebnisse filtern